High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer

Carlo Barone, Antonio Astone, Carlo Garufi, Antonio Grieco, Antonio Cavallaro, Gaetano Netri, Simonetta Rossi, Alessandra Cassano, Enrico Ricevuto, Maria R. Noviello, Gino Gambassi

Research output: Contribution to journalArticle

Abstract

The therapeutic activity of 5-FU in large bowel cancer is enhanced by increasing the intracellular pool of reduced folates. We treated 45 patients with advanced colon cancer with HDFA and 5-FU for 5 consecutive days. None had been given previous radio- or chemotherapy. All had measurable disease. Not one complete response was observed. Thirteen of the 39 evaluable patients showed partial response. Median duration of response was 9+ months. The probability of 50% survival was 15 months for all evaluable patients. There was no case of severe toxicity and the principal toxic effects were oral mucositis and diarrhea. To date, HDFA + 5-FU is one of the most effective treatments for large bowel cancer.

Original languageEnglish
Pages (from-to)1303-1306
Number of pages4
JournalEuropean Journal of Cancer and Clinical Oncology
Volume23
Issue number9
DOIs
Publication statusPublished - 1987

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer'. Together they form a unique fingerprint.

  • Cite this

    Barone, C., Astone, A., Garufi, C., Grieco, A., Cavallaro, A., Netri, G., Rossi, S., Cassano, A., Ricevuto, E., Noviello, M. R., & Gambassi, G. (1987). High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer. European Journal of Cancer and Clinical Oncology, 23(9), 1303-1306. https://doi.org/10.1016/0277-5379(87)90112-X